The Filing Desk

Coherus Oncology

CHRS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CHRS · Last close · November 19, 2026
$0.39
Value Coherus Oncology yourself

Coherus Oncology's revenue rose 59.8% to $42 million in fiscal 2025. Its operating margin was −429.5%, up from −756.6% a year earlier. The diluted share count rose 2.3%.

Coherus Oncology, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001104659-26-025308 Updated
Revenue
$42M
59.8%
Operating margin
−429.5%
327.1 pts
Net income
$168M
489.4%
Free cash flow
—
 
Return on equity
—
 
Market cap
$60M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Coherus Oncology does

Coherus Oncology develops and sells cancer medicines that work with the immune system. Its one marketed product is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, a drug that helps the immune system attack cancer cells. The FDA approved it in October 2023 for nasopharyngeal carcinoma, a cancer of the upper throat, and Coherus launched it in the United States in January 2024.

Coherus developed LOQTORZI with Junshi Biosciences. It earns money from sales of LOQTORZI. It plans to grow sales, add new uses for LOQTORZI and test it in combination with its own pipeline drugs: two mid-stage candidates, tagmokitug and casdozokitug, aimed at liver, head and neck, colorectal and other cancers.

It was called Coherus BioSciences until May 2025, when it changed its name after selling its biosimilar businesses and focusing on new immuno-oncology medicines.

Its biggest risks, as it describes them

  • A limited history of profitability, with only one approved and marketed product.
  • Needing to raise more funds, which may not be available on acceptable terms.
  • Uncertain insurance coverage and reimbursement for its product.
  • Competition from other immuno-oncology drugs, including those that may reach the market first.
  • Heavy regulatory scrutiny of its product and candidates, even after approval.
From Coherus Oncology's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2019 to 2025, earnings per share grew 2.5% a year and net income 11.0% a year, as new shares raised the share count by 60% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments417192118—172
Debt incl. finance leases83————
Net debt (negative means net cash)−335————
Net debt to EBITDA—————
Debt to equity0.8x————
Interest coverage−11.5x−7.9x−5.0x−18.6x−20.1x
Current ratio3.6x2.8x1.4x1.2x1.5x
Quick ratio3.4x2.5x1.2x1.2x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Coherus Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Coherus Oncology reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−46.2%——
Altman Z''−9.10−13.65−20.15
Accruals ratio−11.3%9.1%86.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Coherus Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Coherus OncologyFY2559.8%−429.5%————
Wave Life SciencesFY25−60.5%−504.1%−440.5%———Compare
Editas MedicineFY2525.4%−394.9%−409.3%——2Compare
Voyager TherapeuticsFY25−49.5%−326.6%−334.5%———Compare
Fennec PharmaceuticalsFY25−6.1%−14.1%————Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue190203564763272112572642
Revenue growth532.8%−99.2%−100.0%—33.6%−31.4%−35.4%21.9%−89.7%59.8%
Gross profit———339438269141981828
Research and development2541621109414336319910992109
Operating income−116−232−204108156−264−257−203−200−181
Net income−127−238−20990132−287−292−23828168
Diluted EPS (US$)−3.04−4.48−3.221.231.62−3.81−3.76−2.530.251.43
Diluted shares (millions)4253657384757894115117
Cash flow
Cash from operations−252−200−15928154−37−241−175−20−138
Capital expenditure65127120——
Free cash flow−259−205−16027147−39−243−175——
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation27333534385151432817
Balance sheet at fiscal year end
Cash and short-term investments12512772178541417192118—172
Debt incl. finance leases757677788183————
Total assets178163100409842679481630448258
Total liabilities159132138304561582618823580197
Shareholders' equity2030−3910528198−137−193−13261
Margins and ratios
Gross margin———95.2%92.1%82.4%66.8%38.2%66.9%67.2%
Operating margin−61.0%−14,918.8%—30.3%32.9%−80.8%−121.7%−79.0%−756.6%−429.5%
Net margin−67.0%−15,306.6%—25.2%27.8%−87.9%−138.2%−92.5%108.0%398.4%
Free cash flow margin−136.3%−13,165.8%—7.5%30.9%−11.9%−115.2%−68.1%——
Rule of 40 (growth + FCF margin)396.6%−13,264.9%——64.5%−43.2%−150.6%−46.2%——
Return on capital——————————
Return on equity—−932.9%—269.7%68.5%−151.6%————
Return on assets−65.2%−139.7%−159.8%35.3%21.1%−37.8%−50.3%−42.9%5.3%47.5%
Net debt to EBITDA———−0.9x−2.9x—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Coherus Oncology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Coherus Oncology.